post-operative News
-
Prolonged Analgesia From Bupisome And Bupigel Formulations: From Design And Fabrication To Improved Stability
Based on data from early animal studies, Probudur has indicated post-operative control for up to 96 hours, which is 24 hours longer than the leading product on the market. If we are able to demonstrate a successful Phase III clinical trial, we believe Probudur may represent the first long acting local anesthetic with an opioid sparing label. ...
-
Aprevent VOIS received German NUB approval for the second year in a row!
Germany is one of the largest public healthcare spenders in the world. German NUB (Neue Untersuchungs- und Behandlungsmethode), which stands for New Methods of Treatment and Screening, is a payment scheme for remunerating cost-intensive "innovative" services and technologies that are used in addition to the procedures included in existing DRG-case payment and is only open to ...
-
Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.
ARLINGTON, Mass., May 23, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it has entered into a definitive agreement to sell its commercial portfolio and related intellectual property assets to Alcon Inc. ...
-
GPT Waste’s Head of Business Development completes the Windemere Triathlon
On Sunday, 3rd July, Mike Callaghan – Head of Business Development at GPT Waste Management Ltd completed the Windermere Triathlon in a bid to raise funds for The Joshua Wilson Brain Tumour Charity. The Windermere Triathlon is in no way for the faint hearted. It is a challenge only undertaken by those strong enough, and brave enough to believe they can reach the finish line. Starting with ...
-
Cirrus Research is Ready for Brexit
Following the result of the UK General Election in December 2019, the United Kingdom will be leaving the European Union on January 31st 2020. I’ve covered this topic a few times on our blog and on social media. Still, now we know that the UK will be withdrawing from the EU, I thought it would be in the interests of all our customers and followers, to explain what this means in terms of our ...
-
Bexson Biomedical Announces Participation in the Jeffries Innovation in Mental Health Summit
Bexson Biomedical, Inc., a biopharmaceutical company focused on disrupting the $189 billion small molecule injectable market and enabling home health solutions, today announced that the Company’s management will be participating in the 2022 Jeffries Innovation inMental Health Summit. Bexson’s Chief Executive Officer, Gregg Peterson, and Chief Scientific Officer, Jeffrey Becker, are ...
-
TISSIUM Receives FDA Investigational Device Exemption for Vascular Sealant
TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced today it has received approval from the U.S. Food and Drug Administration for its Investigational Device Exemption application for its vascular sealant. The approval is the most recent validation of TISSIUM’s efforts to develop a unique platform of proprietary ...
By TISSIUM
-
First Patients Treated in First-in-Human Trial for ACTISEAL – Polyganics’ Innovative Liver and Pancreas Sealant Patch
Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, today announced treatment of the first patients in its first-in-human study for ACTISEAL®, its Liver and Pancreas Sealant Patch. The ‘SHIELDS’ trial is a prospective, multicenter study, evaluating the safety and performance of ACTISEAL® in reducing fluid ...
-
Merck Receives Complete Response Letter From US FDA for Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding Merck’s supplemental Biologics License Application (sBLA) seeking approval for KEYTRUDA, the company’s anti-PD-1 therapy, for the treatment of patients with high-risk early-stage triple-negative ...
-
Palisade Bio Announces Inducement Awards Under Inducement Plan For Key New Hires
Palisade Bio (Nasdaq: PALI), a clinical-stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal complications, today announced that it had made equity grants to four new employees under its 2021 Inducement Plan. On May 4, 2022, the Company’s Compensation Committee granted options to four new non-executive employees covering an aggregate of 140,000 shares ...
By Palisade Bio
-
Eagle Pharmaceuticals Takes Equity Stake in, with Option to Acquire, Enalare Therapeutics to Advance Global Development of ENA-001, a Novel Agnostic Respiratory Stimulant
ENA-001 is currently in development for: post-operative respiratory depression, community drug overdose, and Apnea of Prematurity Approval for post-operative respiratory depression expected in 2026 and community drug overdose thereafter ENA-001 works peripherally by inhibiting Big Potassium (BK) ion channels in the carotid bodies, which are located in the neck. By inhibiting these channels, ...
-
Palisade Bio To Present At The H.C. Wainwright BIOCONNECT Virtual Conference And Biotech Showcase
Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announces that they will present at the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10-13, 2022, and at Biotech Showcase taking place January 10-12, 2022. The Palisade Bio management team also will be hosting investor ...
By Palisade Bio
-
Bexson Biomedical Granted USPTO Patent Allowance on Proprietary Formulation Technology, SeValent
Bexson Biomedical, Inc., a biopharmaceutical company focused on disrupting the small molecule injectable market and enabling home health solutions, today announced the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application No. 17/546,880 filed on December 9, 2021 and titled Complexing Agent Salt Formulations of Pharmaceutical Compounds. Bexson’s ...
-
AtriCure Names Two New Members to the Board of Directors
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that Deborah H. Telman and Maggie Yuen have been elected to its Board of Directors. Ms. Telman has spent over 20 years in senior executive roles at global companies. She is Executive Vice President and General Counsel for Organon (NYSE: ...
-
Anteris appoints Chief Medical Officer
Anteris Technologies Ltd (ASX: AVR) (Anteris or the Company) announces the appointment of the internationally recognized Interventional Cardiologist, Dr Chris Meduri MD MPH, as its Chief Medical Officer (CMO). Dr Meduri is a recognized leader in the field of valvular heart disease, serving as the national principle investigator of several valve trials and on numerous steering committees. He has ...
-
Orthopedic Surgeon, Mathew J. Kirsch, Honored by Sonex Health as a Center of Excellence Physician
Dr. Matthew J. Kirsch of Rochester, MN, has been selected by Sonex Health, Inc. as a national Center of Excellence physician for carpal tunnel release (CTR) using the SX-One MicroKnife® and real-time ultrasound guidance. Since adopting the technique more than three years ago, Dr. Kirsch has helped hundreds of patients enjoy rapid recovery. A small incision in the wrist is typically closed ...
-
BioQ Announces agreement with Avanos to Commercialize Ready-to-Use Infusion Products in North America
BioQ Pharma Incorporated, a specialty pharmaceutical company, today announced that it has entered into a Development, Supply, Distribution Agreement with Avanos Medical, Inc. (NYSE: AVNS, “Avanos”). Under the agreement, the parties will work together to obtain appropriate regulatory approvals and commercialize self-contained, infusible, non-opioid post-operative pain pharmaceutical ...
By BioQ Pharma
-
USPTO issues Patent for ground breaking polysaccharide technology platform to Endomedix.
Endomedix announced today that it received a patent of 30 issued claims for its PLEXimine™ Polysaccharide Technology platform for a new class of biomaterials. The patent, “Methods and Compositions for Achieving Hemostasis and Stable Clot Formation”, also covers design features and mechanisms of action for its first product based on the technology. This technology platform ...
-
ITM Executes Option to In-license Targeted Radionuclide Therapy Candidate LuCaFab (ITM-31) for the Treatment of Malignant Brain Tumors
ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the execution of an exclusive licensing option for LuCaFab (now ITM-31), a novel Targeted Radionuclide Therapy candidate for the treatment of malignant glioblastoma. ITM-31 is a carbonic anhydrase XII (CA XII)-specific antibody Fab fragment developed by Helmholtz Munich and coupled with ITM's ...
-
Aatru Medical Announces FDA Clearance and Commercial Launch of the NPSIMS - Negative Pressure Surgical Incision Management System
Aatru Medical, LLC ("Aatru") today announced U.S. Food and Drug Administration (FDA) 510(k) Class II clearance of the NPSIMS™ Negative Pressure Surgical Incision Management System. The NPSIMS utilizes an innovative mode-of-action that eliminates the expensive electromechanical pump, battery, and electronics found in most other negative pressure wound therapy (NPWT) systems being deployed ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you